GE HealthCare expects US regulatory approval for its Photonova Spectra photon-counting CT this year, anticipating initial orders in 2026 and meaningful revenue contribution beginning in 2027. Management described photon-counting CT as a new segment with limited cannibalization and labeled total-body PET/CT opportunity as “blue ocean.”

The company delivered 5% full-year orders growth and 3.5% organic revenue growth in 2025, positioning it for mid-single-digit revenue gains. GE HealthCare reaffirmed its 2026 organic revenue guidance of 3–4%, forecasting 2–3% growth in Q1 with acceleration later in the year.

Innovation investment has risen significantly over the past five years across R&D and cost of goods, aiming for parity with peers. The AVS business saw shorter sales cycles and introduced three products—Vivid Pioneer ultrasound, Allia Moveo interventional platform and LOGIQ R5 software—within three months.

Tariff changes, including IEEPA, 301 and 232 levies, have limited upside due to new duties, but mitigation efforts have reduced tariff impact this year. Any sustained tariff relief is expected to flow through to R&D and SG&A funding without altering long-term investment priorities.